INNOWWIDE aims to bring European highly innovative SMEs to the forefront of international markets by prototyping and shaping a new and unique financial scheme (the “INNOWWIDE Call for proposals”) that will allow them to conduct Viability Assessment Projects (VAPs) in cooperation with local stakeholders, creating the conditions to increase the uptake of European innovative solutions in markets outside Europe. Two calls will be implemented with a total budget of 7,2M€, allowing to fund 120 VAPs (60k€/VAP), and targeting markets of developing countries, large emerging economies (Brazil, Russia, India, China, Mexico) and developed countries with the same allocation for each of these three country categories. The strength of this initiative lies in: (1) the experience of project partners concerning calls for proposals design and management, having 8 European funding agencies among them; (2) a SME-centric approach, to be implemented thanks to the extensive access and links to the European SMEs that project partners have; and (3) an ambitious stakeholder mobilisation plan with a strong focus on third country players thanks to partners international network of delegations (130 offices abroad in 45 countries). Project impact will be evaluated following a holistic, multilevel assessment approach covering European and international dimensions, done at VAP and at call level, and providing information from qualitative and quantitative points of view. This valuable information will be used to draw R&I policy conclusions, that will be shared with relevant policy bodies through the creation and operation of the “INNOWWIDE Policy Working Group”.

TRANSVAC2 is the follow-up project to its successful predecessor project TRANSVAC, the European Network of Vaccine Research and Development funded under FP7. The TRANSVAC2 consortium comprises a comprehensive collection of leading European institutions that propose to further advance with the previous initiative towards the establishment of a fully operational and sustainable European vaccine R&D infrastructure. TRANSVAC2 will support innovation for both prophylactic and therapeutic vaccine development based on a disease-overarching and one-health approach, thereby optimising the knowledge and expertise gained during the development of both human and animal vaccines. This will be achieved by bridging the translational gap in biomedical research, and by supporting cooperation between public vaccine R&D institutions of excellence, related initiatives and networks in Europe, and industrial partners. TRANSVAC2 will complement and integrate with existing European research infrastructures in both the public and private sectors. TRANSVAC2 will function as leverage and innovation catalyst between all stakeholders involved in vaccine R&D in Europe and -by providing integrated and overarching vaccine R&D services- will contribute to the development of effective products to address European and global health challenges, to controlling the burden and spread of infectious diseases, and reinforce the economic assets represented by vaccine developers in Europe. The impact of TRANSVAC2 will be maximised by two external advisory bodies. An independent Scientific & Ethics Advisory Committee will provide recommendations surrounding scientific-technical and ethical issues, whereas the coordination of TRANSVAC2 with other related initiatives and the further promotion of the long-term stability of a European vaccine R&D infrastructure will be supported by a Board of Stakeholders comprising representatives of policy and decision makers, industry associations and European infrastructures.

The overall objectives of the project are to deliver services designed to enhance the innovation management capacity of SMEs in the Netherlands between 1 January 2020 and 31 December 2021. These services will comprise both Key Account Management (KAM) services for SME beneficiaries of the EIC Pilot under H2020 and services to Enhance the Innovation Management Capacities of SMEs. The sub objective for the first category is: to identify weaknesses in the innovation capacities of the SME beneficiaries hindering their growth opportunities and hence their full commercial potential. The Network's Key Account Managers shall identify the coaching needs of the SMEs and shall identify suitable coaches who will be tasked with the addressing of the identified weaknesses. The sub objectives for the second category are: to identify promising SMEs capable of growth and successful internationalisation, to carry out a diagnostic audit to identify gaps in the regional SME innovation management capacity and to develop and implement a tailored action plan to make the innovation system in the company more efficient and effective.